Biotinylated Human CD2 / SRBC Protein, His,Avitag? (MALS verified)
分子別名(Synonym)
CD2,SRBC,LFA-2,T11
表達區(qū)間及表達系統(tǒng)(Source)
Biotinylated Human CD2, His,Avitag (CD2-H82E6) is expressed from human 293 cells (HEK293). It contains AA Lys 25 - Asp 209 (Accession # AAH33583).
Predicted N-terminus: Lys 25
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 24.8 kDa. The protein migrates as 35-43 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景介紹
T細胞表面抗原CD2(亦稱紅細胞受體、LFA-2、LFA-3受體、玫瑰花結(jié)受體、T細胞表面抗原T11/Leu-5及SRBC)是一種表達于T細胞和自然殺傷(NK)細胞表面的I型單次跨膜蛋白。該蛋白屬于免疫球蛋白超家族成員,包含1個免疫球蛋白樣C2型結(jié)構(gòu)域和1個免疫球蛋白樣V型結(jié)構(gòu)域。CD2/SRBC可與其他細胞表面表達的黏附分子相互作用,如人類淋巴細胞功能相關(guān)抗原-3(LFA-3/CD58)或嚙齒類動物的CD48。除介導(dǎo)細胞黏附外,CD2還作為T細胞和NK細胞的共刺激分子發(fā)揮作用。作為T細胞與NK細胞的特異性標(biāo)志物,CD2可通過免疫組織化學(xué)技術(shù)用于組織切片中該類細胞的鑒定。
關(guān)鍵字: CD2;CD2蛋白;CD2重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。